Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.
2.

The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.

Schuster C, Forster K, Dierks H, Elsasser A, Behre G, Simon N, Danhauser-Riedl S, Hallek M, Warmuth M.

Blood. 2003 Jan 15;101(2):655-63. Epub 2002 Sep 12.

3.

Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.

Wendtner CM, Kofler DM, Theiss HD, Kurzeder C, Buhmann R, Schweighofer C, Perabo L, Danhauser-Riedl S, Baumert J, Hiddemann W, Hallek M, Büning H.

Blood. 2002 Sep 1;100(5):1655-61.

4.

A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping.

Dugas M, Schoch C, Schnittger S, Haferlach T, Danhauser-Riedl S, Hiddemann W, Messerer D, Uberla K.

Leukemia. 2001 Dec;15(12):1805-10. No abstract available.

PMID:
11753599
5.
6.

Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.

Warmuth M, Danhauser-Riedl S, Hallek M.

Ann Hematol. 1999 Feb;78(2):49-64. Review.

PMID:
10089019
7.

Two uncommon lymphomas. Case 1: abdominal Burkitt's lymphoma.

Jung C, Gross M, Kronawitter U, Danhauser-Riedl S, Goebel FD, Schlondorff D.

J Clin Oncol. 1999 Feb;17(2):726-7. No abstract available.

PMID:
10080619
8.

Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.

Hallek M, Neumann C, Schäffer M, Danhauser-Riedl S, von Bubnoff N, de Vos G, Druker BJ, Yasukawa K, Griffin JD, Emmerich B.

Exp Hematol. 1997 Dec;25(13):1367-77.

PMID:
9406996
9.

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M.

Cancer Res. 1996 Aug 1;56(15):3589-96.

10.

Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.

Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ, Druker B, Griffin JD, Emmerich B, Ullrich A.

Br J Haematol. 1996 Jul;94(1):5-16.

PMID:
8757502
11.
12.

Interleukin 1 modulates growth of human renal carcinoma cells in vitro.

Koch I, Depenbrock H, Danhauser-Riedl S, Rastetter JW, Hanauske AR.

Br J Cancer. 1995 Apr;71(4):794-800.

13.

Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD).

Danhauser-Riedl S, Hausmann E, Schick HD, Bender R, Dietzfelbinger H, Rastetter J, Hanauske AR.

Invest New Drugs. 1993 May-Aug;11(2-3):187-95.

PMID:
7505268
14.

Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum C, Aapro MS, Bissery MC, Rastetter J, et al.

Eur J Cancer. 1993;29A(14):2009-14.

PMID:
7904173
15.

Lack of therapeutic effects of platelet activating factor antagonists in WEHI-3B leukemia, human xenotransplanted colorectal and lung cancer and Lewis-lung tumor in vivo.

Koenigsmann M, Zafferani M, Danhauser-Riedl S, Reufi B, Houlihan WJ, Thiel E, Berdel WE.

Cancer Lett. 1992 Dec 24;67(2-3):145-56.

PMID:
1483263
16.

Effects of hematopoietic growth factors on malignant nonhematopoietic cells.

Berdel WE, Danhauser-Riedl S, Oberberg D, Zafferani M.

Semin Oncol. 1992 Apr;19(2 Suppl 4):41-5.

PMID:
1553574
17.

Effects of recombinant human erythropoietin on clonogenic growth of primary human tumour specimens in vitro.

Bauer E, Danhauser-Riedl S, De Riese W, Raab HR, Sandner S, Meyer HJ, Neukam D, Hanauske U, Freund M, Poliwoda H, et al.

Eur J Cancer. 1992;28A(10):1769. No abstract available.

PMID:
1389501
18.

Some antagonists of platelet activating factor are cytotoxic for human malignant cell lines.

Danhauser-Riedl S, Felix SB, Houlihan WJ, Zafferani M, Steinhauser G, Oberberg D, Kalvelage H, Busch R, Rastetter J, Berdel WE.

Cancer Res. 1991 Jan 1;51(1):43-8.

19.

Stimulation of clonal growth of human colorectal tumor cells by IL-3 and GM-CSF. Modulation of 5-FU cytotoxicity by GM-CSF.

Berdel WE, Danhauser-Riedl S, Steinhauser G, Rastetter J.

Onkologie. 1990 Dec;13(6):437-43.

PMID:
2092280
20.

Cytotoxic effects of hexadecylphosphocholine in neoplastic cell lines including drug-resistant sublines in vitro.

Danhauser-Riedl S, Himmelmann A, Steinhauser G, Busch R, Vogler WR, Rastetter J, Berdel WE.

J Lipid Mediat. 1990 Sep-Oct;2(5):271-80.

PMID:
2133272
21.

Cross-resistance pattern of cell lines selected for resistance towards different cytotoxic drugs to membrane-toxic phospholipids in vitro.

Himmelmann AW, Danhauser-Riedl S, Steinhauser G, Busch R, Modest EJ, Noseda A, Rastetter J, Vogler WR, Berdel WE.

Cancer Chemother Pharmacol. 1990;26(6):437-43.

PMID:
2225315
22.

Antitumoral activity of a xanthate compound. II. Therapeutic studies in murine leukemia and tumor models in vivo.

Schick HD, Danhauser-Riedl S, Amtmann E, Busch R, Reichert A, Steinhauser G, Rastetter J, Sauer G, Berdel WE.

Cancer Lett. 1989 Jul 15;46(2):149-52.

PMID:
2752384
23.

Antitumoral activity of a xanthate compound. I. Cytotoxicity studies with neoplastic cell lines in vitro.

Schick HD, Amtmann E, Berdel WE, Danhauser-Riedl S, Reichert A, Steinhauser G, Rastetter J, Sauer G.

Cancer Lett. 1989 Jul 15;46(2):143-7.

PMID:
2752383
24.

Therapeutic activity of 1-beta-D-arabinofuranosylcytosine conjugates of lipids in WEHI-3B leukemia in mice.

Berdel WE, Okamoto S, Danhauser-Riedl S, Hong CI, Winton EF, West CR, Rastetter J, Vogler WR.

Exp Hematol. 1989 May;17(4):364-7.

PMID:
2707318
25.
26.

Phase I trial of the polyelectrolyte carbetimer administered i.v. once every four weeks.

Fromm M, Berdel WE, Schick HD, Danhauser-Riedl S, Fink U, Remy W, Reichert A, Ankele A, Präuer HW, Siewert JR, et al.

Invest New Drugs. 1988 Sep;6(3):189-94.

PMID:
3192384

Supplemental Content

Loading ...
Support Center